11.49

6.69% 0.72

Neurogene Inc (NGNE)

Overview News Price History Financials Discussions Forecast

Neurogene Inc stock is traded at $11.49, with a volume of 189.97K. It is up +6.69% in the last 24 hours and down -31.89% over the past month. Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Previous Close:

$10.77

Open:

$10.75

24h Volume:

189.97K

Relative Volume:

0.70

Market Cap:

$155.31M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+28.09%

1M Performance:

-31.89%

6M Performance:

-78.29%

1Y Performance:

-65.84%

1-Day Range:

$10.46

$11.54

1-Week Range:

$8.995

$11.96

52-Week Range:

$6.875

$74.49

Neurogene Inc Stock (NGNE) Company Profile

Name

Neurogene Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

(877) 237-5020

Address

535 W 24TH STREET, NEW YORK

Employee

107

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

NGNE's Discussions on Twitter

Compare NGNE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NGNE Neurogene Inc	11.49	155.31M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Neurogene Inc Stock (NGNE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-27-24	Initiated	BMO Capital Markets	Outperform
Jun-11-24	Initiated	Robert W. Baird	Outperform
Apr-29-24	Initiated	Leerink Partners	Outperform
Mar-21-24	Initiated	William Blair	Outperform
Jan-08-24	Initiated	H.C. Wainwright	Buy
Jan-05-24	Initiated	Stifel	Buy
Jan-04-24	Initiated	TD Cowen	Outperform

View All

Neurogene Inc Stock (NGNE) Latest News

Apr 15, 2025

Wellington Management Group LLP Grows Stock Holdings in Neurogene Inc. (NASDAQ:NGNE) - The AM Reporter

Apr 15, 2025

BMO cuts Neurogene stock target to $16 from $45, keeps Outperform By Investing.com - Investing.com South Africa

Apr 15, 2025

Wellington Management Group LLP Increases Stock Holdings in Neurogene Inc. (NASDAQ:NGNE) - Defense World

Apr 15, 2025

JPMorgan Chase & Co. Purchases 476,418 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World

Apr 15, 2025

Neurogene (NASDAQ:NGNE) Given New $16.00 Price Target at BMO Capital Markets - Defense World

Apr 15, 2025

Apr 14, 2025

Neurogene Inc. Amends Agreement, Issues Warrants By Investing.com - Investing.com South Africa

Apr 14, 2025

Neurogene Inc. Amends Agreement, Issues Warrants - Investing.com

Apr 14, 2025

Neurogene Amends Agreement With Baker Bros To Increase Nomination Threshold - marketscreener.com

Apr 14, 2025

BMO cuts Neurogene stock target to $16 from $45, keeps Outperform - Investing.com Canada

Apr 14, 2025

Apr 07, 2025

NGNE stock touches 52-week low at $8.35 amid market challenges - Investing.com Australia

Apr 07, 2025

NGNE stock touches 52-week low at $8.35 amid market challenges By Investing.com - Investing.com South Africa

Apr 07, 2025

Apr 03, 2025

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome - BioSpace

Apr 03, 2025

Apr 02, 2025

Neurogene reports progress in gene therapy regulation technology By Investing.com - Investing.com Canada

Apr 02, 2025

Neurogene reports progress in gene therapy regulation technology - Investing.com

Apr 02, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Investors to Inquire about Securities Investigation - ACCESS Newswire

Apr 02, 2025

Mar 29, 2025

Q1 Earnings Estimate for Neurogene Issued By HC Wainwright - The AM Reporter

Mar 29, 2025

Mar 28, 2025

What is HC Wainwright’s Estimate for Neurogene Q1 Earnings? - Defense World

Mar 28, 2025

Neurogene Inc. (NASDAQ:NGNE) Receives $59.80 Average PT from Brokerages - Defense World

Mar 28, 2025

What is William Blair’s Forecast for Neurogene Q1 Earnings? - Defense World

Mar 28, 2025

What is Leerink Partnrs’ Forecast for Neurogene Q1 Earnings? - Defense World

Mar 28, 2025

Mar 27, 2025

Neurogene Reports 2024 Financial Results and Advances in Rett Syndrome Trial - MSN

Mar 27, 2025

PNC Financial Services Group Inc. Makes New $71,000 Investment in Neurogene Inc. (NASDAQ:NGNE) - Defense World

Mar 27, 2025

Analyzing Neurogene (NASDAQ:NGNE) & Rapport Therapeutics (NASDAQ:RAPP) - Defense World

Mar 27, 2025

Mar 26, 2025

Neurogene (NASDAQ:NGNE) Receives Outperform Rating from William Blair - Defense World

Mar 26, 2025

Stifel maintains Buy on Neurogene stock with $46 target By Investing.com - Investing.com UK

Mar 26, 2025

Neurogene (NASDAQ:NGNE) Given New $50.00 Price Target at HC Wainwright - Defense World

Mar 26, 2025

Mar 24, 2025

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates - BioSpace

Mar 24, 2025

Neurogene Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 24, 2025